Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALPL | P05186 | 9/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14397331 | 0.91 | MAPK1 (0.50) | GAAMAPK1ALPLMAPTRAB9A | |
| SCHEMBL14397160 | 0.79 | HCAR3 (0.47) | ALPLMAPTRAB9ANPC1CCNA2 | |
| SCHEMBL286531 | 0.79 | MAPK1 (0.65) | GAAMAPK1ALPLMAPTRAB9A | |
| Hydrochloric Acid SCHEMBL286530 | 0.77 | MAPK1 (0.62) | GAAMAPK1ALPLMAPTRAB9A | |
| SCHEMBL23854654 | 0.72 | MAPK1 (0.59) | GAAMAPK1ALPLMAPTRAB9A | |
| SCHEMBL16534089 | 0.69 | MAPK1 (0.51) | GAAMAPK1ALPLMAPTRAB9A | |
| SCHEMBL1662796 | 0.67 | CHEK1 (0.56) | GAAMAPK1ALPLMAPTLMNA | |
| SCHEMBL23513527 | 0.67 | NPC1 (0.55) | RAB9ASMN1; SMN2NPC1LMNACCNA2 | |
| SCHEMBL1498628 | 0.66 | MAPK1 (0.59) | GAAMAPK1ALPLMAPTRAB9A | |
| SCHEMBL25426462 | 0.64 | NPC1 (0.59) | MAPTRAB9APOLBSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481494-B2 | Compounds for the treatment of diseases related to protein misfolding | UNIVERSITAT DUISBURG-ESSEN (DE) | 2013-07-09 | — | — | US | disclosed |
| US-20120270795-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES RELATED TO PROTEIN MISFOLDING | UNIVERSITAT DUISBURG-ESSEN (DE) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270795-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES RELATED TO PROTEIN MISFOLDING | APP, PRNP, PSEN1 | GAA 101/4885MAPK1 1482/4885ALPL 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.